Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic hyoscine butylbromide to prevent death rattle in the dying phase
2016-002287-14Phase 3Active
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial comparing Prophylactic hyoscine butylbromide with Placebo or standard care control (2 arms). Primary endpoint: Incidence of clinically significant death rattle. Started Nov 2016; status: active.
02
Drugs
hyoscine butylbromide
Beyond the preview
Go deeper on 2016-002287-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002287-14.